Angina

Clinical Trial Finder

Many patients with angina are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis

Condition:   Stable Angina
Intervention:   Device: Drug-eluting stent
Sponsors:   Seoul National University Hospital;   Ajou University School of Medicine;   Keimyung University Dongsan Medical Center;   Inje University
Not yet recruiting - verified February 2016

MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: MDCO-216;   Drug: Placebo
Sponsors:   The Medicines Company;   The Cleveland Clinic
Recruiting - verified February 2016

Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Condition:   Acute Coronary Syndrome
Intervention:   Other: This is a non-interventional study
Sponsor:   Drug Safety Research Unit, Southampton, UK
Recruiting - verified February 2016

Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic

Conditions:   Acute Coronary Syndrome;   Heart Failure;   Other Cardiac Conditions Among Cardiac Rehabilitation Participants
Interventions:   Other: B-MOBILE-CARDIAC smartphone application;   Behavioral: Cardiac rehabilitation as usual
Sponsor:   The Miriam Hospital
Not yet recruiting - verified February 2016

Knowledge Translation for Patients With Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Intervention:   Behavioral: knowledge translation
Sponsors:   Montreal General Hospital;   Sanofi;   Canadian Institutes of Health Research (CIHR);   Fonds de la Recherche en Santé du Québec
Completed - verified January 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events (OXI)

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Recruiting - verified February 2016

Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study

Condition:   Unstable Angina Pectoris
Interventions:   Drug: Pulverized ticagrelor sublingually;   Drug: Pulverized ticagrelor orally;   Drug: Integral ticagrelor
Sponsor:   Collegium Medicum w Bydgoszczy
Recruiting - verified February 2016

Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy

Conditions:   Angina, Stable;   Angina, Unstable;   Anticoagulants
Interventions:   Device: COBRA PzF;   Device: DES
Sponsor:   CeloNova BioSciences, Inc.
Recruiting - verified February 2016

ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)

Condition:   Acute Coronary Syndrome
Interventions:   Behavioral: Nurse-led Intensive Secondary Prevention Programme;   Behavioral: Usual Treatment
Sponsor:   Azienda Ospedaliero-Universitaria di Parma
Recruiting - verified February 2016

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified February 2016

Prospective Registry of Acute Coronary Syndromes in Ferrara

Condition:   Acute Coronary Syndromes
Intervention:   Other: prospective collection of data and follow-up
Sponsor:   University Hospital of Ferrara
Recruiting - verified January 2016

Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients

Condition:   Acute Coronary Syndrome (ACS)
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified February 2016

An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions

Conditions:   Coronary Artery Disease;   Atherosclerosis, Coronary;   Myocardial Ischemia;   Ischemic Heart Disease;   Acute Coronary Syndrome;   Angina Pectoris
Interventions:   Device: Orsiro DES;   Device: Xience DES
Sponsors:   Biotronik, Inc.;   Biotronik AG;   Harvard Clinical Research Institute;   Medstar Research Institute
Recruiting - verified February 2016

Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes

Conditions:   Chronic Obstructive Pulmonary Disease;   Acute Coronary Syndromes
Intervention:   Other: screening test
Sponsor:   University Hospital of Ferrara
Active, not recruiting - verified September 2015

Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease

Conditions:   Coronary Artery Disease;   Endothelial NO-synthase
Intervention:  
Sponsor:   Heinrich-Heine University, Duesseldorf
Recruiting - verified October 2015

Exercise as a Life-long Medicine in Patients With Coronary Artery Disease

Conditions:   Cardiovascular Diseases;   Myocardial Infarction;   Angina (Stable)
Interventions:   Behavioral: high-intensity exercise training;   Behavioral: web-based follow-up program;   Behavioral: usual care
Sponsors:   Norwegian University of Science and Technology;   St. Olavs Hospital;   Levanger Hospital
Recruiting - verified February 2016

Multidetector Coronary CT In Vasospastic Angina

Condition:   Vasospastic Angina
Interventions:   Procedure: Positive CAG with EG test;   Procedure: Negative CAG with EG test
Sponsor:   Dong-A University
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Epoetin alfa
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis.

Condition:   Anemia
Interventions:   Drug: Roxadustat;   Drug: Placebo
Sponsors:   AstraZeneca;   FibroGen
Recruiting - verified February 2016

Absorb IV Randomized Controlled Trial

Conditions:   Coronary Artery Disease;   Coronary Artery Stenosis;   Coronary Disease;   Coronary Stenosis
Interventions:   Device: Absorb BVS;   Device: XIENCE
Sponsor:   Abbott Vascular
Recruiting - verified February 2016

A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Losmapimod 7.5 mg twice daily;   Drug: Placebo twice daily
Sponsors:   GlaxoSmithKline;   The TIMI Study Group
Recruiting - verified February 2016

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 90 days DAPT;   Drug: Treatment 360 days DAPT
Sponsor:   Diagram B.V.
Recruiting - verified February 2016

Essential Hypotension and Adaptability Registry

Conditions:   Blood Pressure;   Depression;   Panic Attack;   Fibromyalgia;   POTS;   Inappropriate Sinus Tachycardia;   Coronary Heart Disease;   Acute Coronary Syndrome (ACS);   Acute Myocardial Infarction (AMI);   Cerebrovascular Disease (CVD);   Transient Ischemic Attack (TIA);   Atrial Fibrillation;   Diabetes Mellitus;   Cancer;   Systolic Heart Failure;   Diastolic Heart Failure;   Chronic Fatigue Syndrome;   Syncope;   Vasovagal Syncope
Intervention:  
Sponsor:   CES University
Recruiting - verified February 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Conditions:   Venous Thrombosis;   Pulmonary Embolism;   Atrial Fibrillation;   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Standard of care
Sponsor:   Bayer
Recruiting - verified January 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease

Condition:   Prevention & Control
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Aspirin;   Drug: Aspirin placebo;   Drug: Rivaroxaban placebo;   Drug: Pantoprazole
Sponsors:   Bayer;   Hamilton Health Sciences Corporation, Population Health Research Institute
Recruiting - verified February 2016

Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions

Condition:   Coronary Heart Disease
Intervention:   Device: Resolute stents
Sponsors:   Fujian Medical University;   Jetmed(Beijing)Co.,Ltd.
Recruiting - verified February 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Condition:   Acute Coronary Syndrome
Interventions:   Drug: alirocumab;   Drug: placebo
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified February 2016

TAKO-TSUBO Cardiomyopathy and Genetic

Conditions:   Tako-TSUBO Cardiomyopathy;   Acute Coronary Syndrome
Intervention:  
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Fédération Française de Cardiologie
Active, not recruiting - verified February 2016

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Conditions:   Infection;   Hypertension;   Pain;   Reflux;   Edema;   Hyperlipidemia;   Hypotension;   Hypercholesterolemia;   Sedation;   Anxiolysis;   Benzodiazepine Withdrawal;   Bipolar Disorder;   Autistic Disorder;   Schizophrenia;   Influenza Treatment or Prophylaxis;   Acute Decompensated Heart Failure;   Stable Angina;   Life-threatening Fungal Infections;   Nosocomial Pneumonia;   Community Acquired Pneumonia;   Acute Bacterial Exacerbation of Chronic Bronchitis;   Complicated Skin and Skin Structure Infections;   Uncomplicated Skin and Skin Structure Infections;   Chronic Bacterial Prostatitis;   Complicated Urinary Tract Infections;   Acute Pyelonephritis;   Uncomplicated Urinary Tract Infections;   Inhalational Anthrax (Post-Exposure);   Infantile Hemangioma;   Withdrawal;   Inflammation;   Bacterial Septicemia;   Cytomegalovirus Retinitis;   Herpes Simplex Virus;   Adenovirus;   Brain Swelling;   Airway Swelling;   Adrenal Insufficiency;   Anxiety;   Nausea;   Vomiting;   Convulsions;   Muscle Spasms;   Seizures;   Epilepsy;   Bartonellosis;   Brucellosis;   Cholera;   Plague;   Psittacosis;   Q Fever;   Relapsing Fever;   Rocky Mountain Spotted Fever;   Trachoma;   Tularemia;   Typhus Fever;   Bronchospasm;   Cardiac Arrest;   Hypersensitivity Reaction;   Cyanide Poisoning;   Acute Bacterial Sinusitis;   Bacterial Meningitis;   Sepsis;   Gastroparesis;   Opioid Addiction;   Migraines;   Headaches
Intervention:   Drug: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Sponsors:   Daniel Benjamin;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   The EMMES Corporation;   OpAns, LLC
Recruiting - verified February 2016

A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Completed - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome

Condition:   Coronary Heart Disease
Interventions:   Drug: Evidence-based medical care for Acute Coronary Syndrome;   Drug: Placebo;   Drug: dalcetrapib
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Exercise-training Before Coronary Artery Bypass Graft (CABG)

Conditions:   Angina;   Coronary Artery Disease
Intervention:   Behavioral: Exercise training
Sponsor:   Norwegian University of Science and Technology
Recruiting - verified February 2016

Postmenopausal Hormone Therapy in Unstable Angina

Conditions:   Angina, Unstable;   Cardiovascular Diseases;   Coronary Disease;   Heart Diseases;   Postmenopause
Interventions:   Drug: estrogen replacement therapy;   Drug: estrogens;   Drug: progesterone;   Drug: hormone replacement therapy
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2005